Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Author:

Richardson Paul G.1,Trudel Suzanne2,Quach Hang3,Popat Rakesh4,Lonial Sagar5,Orlowski Robert Z.6,Kim Kihyun7,Mateos María-Victoria8,Pawlyn Charlotte910,Ramasamy Karthik11,Martinez-Lopez Joaquín12,Spirli Alessia13,Casas-Avilés Ignacio14,Gong Jing15,Amatangelo Michael15,Katz Jessica15,Maciag Paulo15,Peluso Teresa13,Bahlis Nizar J.16

Affiliation:

1. 1Dana-Farber Cancer Institute, Boston, MA

2. 2Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

3. 3St. Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Australia

4. 4NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom

5. 5Winship Cancer Institute, Emory University, Atlanta, GA

6. 6Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

7. 7Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan Univ. Sch. of Med. Samsung Medical Center, Seoul, Korea, Republic of (South)

8. 8University Hospital of Salamanca/IBSAL, Salamanca, Spain

9. 9The Royal Marsden NHS Foundation, London, United Kingdom

10. 10The Institute of Cancer Research, London, United Kingdom

11. 11Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

12. 12Department of Hematology, Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid, Spain

13. 13Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

14. 14Hospital San Pedro de Alcántara, Cáceres, Spain

15. 15Bristol Myers Squibb, Princeton, NJ

16. 16University of Calgary, Calgary, Canada

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3